Michael Shulman is the Editor of ChangeWave Biotech Investor, a newsletter advisory service that follows life sciences and biotech stocks. He also served as Managing Director of Research for ChangeWave Research for four years, where he produced technology and healthcare research for financial institutions.

Michael joined ChangeWave after spending 20 years in various high-tech industries. He began his career doing in-depth company and market analysis for a variety of companies, building databases and simulation models to estimate the success of various technologies across a wide range of market segments. He moved "inside" the high-tech community as a manager at high-tech companies including AT&T.

Michael was an early private investor in several Internet start-ups, notably XOOM.com (which went public in 1998 and was bought by NBC in 1999) and brings a unique perspective to the ChangeWave research effort, as a combination of technologist, investor and financial analyst.

He has been published in a variety of trade and general business publications, including the "Los Angeles Times," is a regular panel member on the FOX Business Channel and has appeared frequently on CNBC's "Squawk Box.”

Prior to taking on his current role as Editor of the ChangeWave Biotech Investor, he was Editor of ChangeWave Hedge Fund Investing and ChangeWave Insight, products designed for the institutional investor. He is also the editor of ChangeWave Shorts, a leading service for individual short side investors based on fundamental research.

Visit his blog: Biotech Blitz